A Three-Part Trial to Qualify [11C]MK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 PAM Receptor Density Quantification in the Human Brain

Trial Profile

A Three-Part Trial to Qualify [11C]MK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 PAM Receptor Density Quantification in the Human Brain

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs MK 6884 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 6 Oct 2017 to 18 Dec 2017.
    • 28 Sep 2017 Planned primary completion date changed from 6 Oct 2017 to 18 Dec 2017.
    • 04 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top